about
A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosisRepeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.Gene expression changes associated with the airway wall response to injury.Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafinLung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium.Variability of the Sheep Lung Microbiota.Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.The potential of cyclosporin A as an anti-tumour agent.Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.Optimizing aerosol gene delivery and expression in the ovine lung.Human-specific cystic fibrosis transmembrane conductance regulator antibodies detect in vivo gene transfer to ovine airways.An epidemiological survey on the prevalence of equine peripheral dental caries in the United Kingdom and possible risk factors for its development.Chemokine and cytokine expression in murine intestinal epithelium following Nippostrongylus brasiliensis infection.Grazing livestock are exposed to terrestrial cyanobacteria.Ovine induced pluripotent stem cells are resistant to reprogramming after nuclear transfer.Microbiota in Exhaled Breath Condensate and the Lung.Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.Comparing microbiotas in the upper aerodigestive and lower respiratory tracts of lambs.Validation of recombinant Sendai virus in a non-natural host model.Transgenic sheep designed for transplantation studies.Secreted Gaussia luciferase as a sensitive reporter gene for in vivo and ex vivo studies of airway gene transfer.Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP.Age-related differences in the respiratory microbiota of chickens.The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.Plasmid DNA molecules complexed with cationic liposomes are protected from degradation by nucleases and shearing by aerosolisation.An immunocytochemical assay to detect human CFTR expression following gene transfer.Electroporation enhances reporter gene expression following delivery of naked plasmid DNA to the lung.Factors affecting the efficiency of aerosolized salbutamol delivery via a metered dose inhaler and equine spacer device.Evaluation of nebulised hay dust suspensions (HDS) for the diagnosis and investigation of heaves. 1: Preparation and composition of HDS.Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy.Nebulisation of synthetic lamellar lipids mitigates radiation-induced lung injury in a large animal modelBrdU pulse labelling in vivo to characterise cell proliferation during regeneration and repair following injury to the airway wall in sheepEnhanced Lung Gene Expression After Aerosol Delivery of Concentrated pDNA/PEI ComplexesLung disease in the cystic fibrosis mouse exposed to bacterial pathogensAnalysis of airway epithelial regeneration and repair following endobronchial brush biopsy in sheep
P50
Q28071263-460281FB-994F-400D-A854-6433A450B970Q34483772-D44F2CC6-F2FF-4F7D-830A-12F796089B36Q34672278-33EA9081-B66E-4821-ADC5-450B198C8875Q35106451-43B017FF-8A56-4D4B-9DBB-A80EF7A4A880Q36257805-552ED713-3587-4BF4-86EE-AFCA3527E55BQ37122357-5550150F-ACEC-4180-AA30-FBA629691016Q37616952-BAE5AFBD-AE73-43C9-9F85-E1741150356EQ37959817-8AF2C50F-85A7-467B-BC55-A616C8CBAF0EQ38439122-230EFB28-2D4B-419E-A56E-201C858B2B41Q38464450-3A6711E0-B5E6-4A34-B612-B6B56F3271DBQ38469478-CBEC6AE2-CBC6-415F-AEDA-B1B14BBE09DBQ40648521-0B305A09-D782-49DF-B018-2750C2550349Q40747493-91F4B1E9-57B8-494C-9DFC-4D8EA15272DEQ41366095-4C272AE5-F900-4DA4-89A4-13A69F72CD63Q41683960-711ABC2C-8032-4AF6-9A2F-A4D16B766A06Q42232425-FC86EECF-30CF-4BC1-A07D-C2EC9D3E0F3EQ42257473-7EF36352-4B2F-4CAE-9773-C5AC6384F356Q42617527-6038454E-D178-40AE-B203-217D4B436865Q43930000-38AEF324-3920-40B5-BB27-90B611B6032DQ43972457-86E3FA20-1D30-42C9-9273-3FF76810E683Q44576080-04AF9408-595B-42D5-9A22-EDB53E034887Q44719830-750D3F5B-7867-41F7-AB0A-13099706B4A5Q45793342-9B99ED2A-4395-47AD-9D64-A30C1952AEFEQ45856930-9AB562F5-9330-45B5-AEFD-7C62346DCCB7Q45879192-A5F0D170-DFFC-4409-844C-52455B423DC1Q45887025-F3A06C24-7ADA-44AC-93C9-26E666C4D44AQ50690475-9D7322A5-DD2C-487E-B221-D0179E463CEEQ51173307-4C9C2670-3A92-47E6-883A-25E4A525ECF7Q51710722-6E2434BA-D756-4216-A28B-0EAB35252DE6Q51721280-364C17DA-0C3F-4793-9A94-9EE8277E57D3Q58761891-9CECB96E-71B0-4E4D-A90E-E54957AF802AQ59034712-DDFB45A7-2964-4467-B1BA-80DFA1574029Q61703770-36A14A1E-6347-4501-AC62-227C713FAFC9Q71698854-33DDDBAB-88C7-4CB0-A787-51861B0E2AA8Q84898033-6E7F8F39-0337-4261-B45A-CAEFF8506A47
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gerry McLachlan
@ast
Gerry McLachlan
@en
Gerry McLachlan
@es
Gerry McLachlan
@nl
type
label
Gerry McLachlan
@ast
Gerry McLachlan
@en
Gerry McLachlan
@es
Gerry McLachlan
@nl
prefLabel
Gerry McLachlan
@ast
Gerry McLachlan
@en
Gerry McLachlan
@es
Gerry McLachlan
@nl
P106
P31
P496
0000-0001-5362-9804